

**Minutes of the June 22, 2012
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Debra Farver, PharmD; Dana Darger, RPh; Timothy Soundy, MD; Bill Ladwig, RPh; James Engelbrecht, MD; Michelle Baack, MD; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD, Rick Holm, MD

DSS staff present

Mike Jockheck, RPh
Ann Schwartz, Dep. Director, Medical Services

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the June 22, 2012 meeting were presented. D. Farver made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for April 2012. There were a total of 2,738 PAs processed in the month of April, with 98.87% of those requests responded to in less than 8 hours. There were 2,247 (82%) requests received electronically and 491 (18%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/01/2012 – 03/31/2012. The top five classes were antipsychotics, cerebral stimulants, amphetamines, corticosteroids (respiratory tract), and central nervous system agents, misc. The top 15 therapeutic classes make up 38.30% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 16.69% of total claims. Committee members asked that inhaled corticosteroids and antiretrovirals be included on the next agenda.

Antipsychotics Review

C. Rieth reviewed data for antipsychotics. Previous recommendations made by the committee were included with the review along with new recommendations made by Dr. Farver and Dr. Soundy. P. Arends, representing NAMI, spoke to the committee. After review, the committee made the following changes to the proposed PA form:

1. Add intermittent explosive disorder, pervasive developmental disorder, and tourettes to the list of diagnoses.
2. Add developmental pediatrician, child/adolescent psychiatrist and pediatric neurologist to the list of specialists involved in care of recipients <6 years of age.
3. Change FDA approved indication to 'included indication'.
4. Change two atypical antipsychotics must involve psychiatrist or associated mid-level practitioner consult to 'two atypical antipsychotics must involve psychiatrist or mid-level practitioner in collaboration with a psychiatrist'.

M. Baack made a motion to approve the amended PA form. B. Ladwig seconded the motion. The motion was approved unanimously.

Lidoderm Review

C. Rieth presented clinical information and utilization for Lidoderm. J. Engelbrecht made a motion to place Lidoderm on prior authorization for FDA approved indication. L. Petrick seconded the motion. The motion was approved unanimously. The PA form will be reviewed at the next meeting.

Brilinta Review

C. Rieth presented clinical information and utilization for Brilinta. There was no public comment. This topic was tabled.

Early Refill Review

M. Jockheck reviewed early refill information with the committee. There was no public comment. The committee requested that more information be provided at the next meeting including a list of the drugs that fall into the 22-24 day early refill range.

Onfi Review

C. Rieth reviewed Onfi clinical information and utilization. There was no public comment. J. Engelbrecht made a motion to place Onfi on prior authorization for FDA approved indication. R. Holm seconded the motion. The motion was approved unanimously. The PA form will be reviewed at the next meeting.

Topical Corticosteroid Review

C. Rieth reviewed topical corticosteroid clinical information and utilization. This topic was tabled.

Actinic Keratoses Review

C. Rieth reviewed actinic keratoses clinical information and utilization. This topic was tabled.

The next meeting date is scheduled for September 14, 2012. A motion was made by M. Baack at 3:00pm to adjourn the SD Medicaid P&T meeting. K. Oehlke seconded the motion. Motion passed unanimously and the meeting was adjourned.